As of fiscal year 2017/2018, prescription drug Janumet (with the ingredients sitagliptin and metformin) cost, on average, about 968 Canadian dollars per beneficiary. Janumet is a widely used medicine to treat type 2 diabetes.
Average cost per beneficiary of select prominent drugs in Canada's public drug plans in 2017/2018 (in Canadian dollars)*
* The public drug plans include British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick,
Nova Scotia, Prince Edward Island, Newfoundland and Labrador, and the Non-Insured Health Benefits Program.
This analysis only includes data for beneficiaries that met their deductible and received public reimbursement.
This feature is limited to our corporate solutions.
Please contact us to get started with full access to dossiers, forecasts, studies and international data.
Corporate Account
Statista Accounts:
Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account!
Single Account
Your perfect start with Statista
Instant access to 1m statistics
Download in XLS, PDF & PNG format
Detailed references
$59 / Month *
Corporate Account
Full access
Corporate solution including all features.
* All products require an annual contract.
Prices do not include sales tax.
Statista Accounts:
Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.
PMPRB. (September 6, 2019). Average cost per beneficiary of select prominent drugs in Canada's public drug plans in 2017/2018 (in Canadian dollars)* [Graph]. In Statista. Retrieved February 28, 2020, from https://www.statista.com/statistics/487519/cost-per-beneficiary-of-select-drugs-in-canada-s-public-drug-plan/
PMPRB. "Average cost per beneficiary of select prominent drugs in Canada's public drug plans in 2017/2018 (in Canadian dollars)*." Chart. September 6, 2019. Statista. Accessed February 28, 2020. https://www.statista.com/statistics/487519/cost-per-beneficiary-of-select-drugs-in-canada-s-public-drug-plan/
PMPRB. (2019). Average cost per beneficiary of select prominent drugs in Canada's public drug plans in 2017/2018 (in Canadian dollars)*. Statista. Statista Inc.. Accessed: February 28, 2020. https://www.statista.com/statistics/487519/cost-per-beneficiary-of-select-drugs-in-canada-s-public-drug-plan/
PMPRB. "Average Cost per Beneficiary of Select Prominent Drugs in Canada's Public Drug Plans in 2017/2018 (in Canadian Dollars)*." Statista, Statista Inc., 6 Sep 2019, https://www.statista.com/statistics/487519/cost-per-beneficiary-of-select-drugs-in-canada-s-public-drug-plan/
PMPRB, Average cost per beneficiary of select prominent drugs in Canada's public drug plans in 2017/2018 (in Canadian dollars)* Statista, https://www.statista.com/statistics/487519/cost-per-beneficiary-of-select-drugs-in-canada-s-public-drug-plan/ (last visited February 28, 2020)
We use cookies to personalize contents and ads, offer social media features, and analyze access to our website. In your browser settings you can configure or disable this, respectively, and can delete any already placed cookies. For details, please see your browser’s Help section (by pressing F1). Please see our privacy statement for details about how we use data.
